Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Semaglutide cuts major heart events, but researchers still cannot fully explain why (opens in a new tab)

news-medical.net · 2026-09-27

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One key claim is not backed by the study. One other point was not covered by the paper.

  • 3 supported
  • 1 not supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim isn't supported by the study. Three of five check out. One claim the study doesn't address.

  • 3 supported
  • 1 not supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not supportedThe study, published in the European Heart Journal, was a pre-specified mediation analysis of the SELECT trial in 17,604 adults with overweight or obesity and established cardiovascular disease without diabetes.View evidenceHide evidence

Why this verdict

The population description is broadly supported, but the story calls the mediation analysis 'pre-specified' whereas the paper profile repeatedly characterizes it as a post hoc secondary mediation analysis. The 17,604 sample size and European Heart Journal publication detail are not supplied in the abstract-level profile, but the pre-specified/post hoc conflict is the material issue.

1

Study evidence

SELECT reported a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo; this analysis tested mediation of that effect.20% reduction in MACE (overall SELECT result)

“In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index ≥27 kg/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo.”
Claim 2 of 5Not coveredThe study did not establish which additional mechanisms explained the remaining effect, but the authors suggested other unidentified pathways may contribute to semaglutide's cardiovascular protection and described possibilities such as vascular and anti-inflammatory effects as speculative.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the general point that the analysis could not definitively attribute semaglutide's cardiovascular benefit to the evaluated risk factors and that further investigation of additional mediators is warranted. However, the specific assertion that the authors described vascular and anti-inflammatory mechanisms as speculative is not available in the supplied abstract-level evidence.

1

Study evidence

SELECT reported a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo; this analysis tested mediation of that effect.20% reduction in MACE (overall SELECT result)

“In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index ≥27 kg/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo.”
Claim 3 of 5SupportedA detailed analysis of the SELECT trial examined how much of semaglutide's reduction in major heart events could be attributed to changes in weight, inflammation, blood glucose, and other cardiovascular risk factors.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that this paper analyzed potential mediation of SELECT's MACE reduction by changes in candidate cardiometabolic risk factors, including body weight, hsCRP/inflammation, HbA1c/blood glucose, lipids, blood pressure, kidney measures, and combinations of mediators.

1

Study evidence

SELECT reported a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo; this analysis tested mediation of that effect.20% reduction in MACE (overall SELECT result)

“In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index ≥27 kg/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo.”
Claim 4 of 5SupportedThe primary SELECT trial had previously shown that weekly semaglutide at a target dose of 2.4 mg reduced major adverse cardiovascular events by 20% compared with placebo.View evidenceHide evidence

As stated20%

Why this verdict

The profile quotes the abstract stating that in SELECT, weekly subcutaneous semaglutide at target dose 2.4 mg in adults with pre-existing cardiovascular disease, BMI ≥27 kg/m2, and no diabetes significantly reduced MACE by 20% versus placebo. Because SELECT was an RCT, the story's causal framing for the primary trial result is supported at this depth.

1

Study evidence

SELECT reported a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo; this analysis tested mediation of that effect.20% reduction in MACE (overall SELECT result)

“In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index ≥27 kg/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo.”
Claim 5 of 5SupportedIn the mediation model, conventional risk factors such as body weight, blood pressure, cholesterol, and blood glucose had a joint mediation point estimate of 31.4%, leaving about 68.6% of the treatment effect unaccounted for in the point estimate.View evidenceHide evidence

As stated31.4% mediated; 68.6% unaccounted for

Why this verdict

The profile reports that multivariable joint mediation for all potential mediators combined was estimated at 31.4%. Describing the complementary point estimate as about 68.6% unaccounted for is arithmetically consistent, and the claim specifies that this is the point estimate. The important uncertainty around this estimate is addressed elsewhere in the story's caveats.

1

Study evidence

SELECT reported a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo; this analysis tested mediation of that effect.20% reduction in MACE (overall SELECT result)

“In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index ≥27 kg/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo.”
2

Study evidence

Supplementary analyses suggested unreliability of estimates for body weight and waist circumference, potentially due to differing relationships of body weight and waist change to MACE between treatment arms.

“Supplementary analyses suggested unreliability of estimates for body weight and waist circumference, potentially due to differing relationship of body weight and waist change to MACE between treatment arms.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper is a post hoc secondary counterfactual mediation analysis of the SELECT randomized trial, not a pre-specified mediation analysis as presented by the story.

    The story explicitly describes the analysis as pre-specified, while the supplied paper profile labels it post hoc. This is an interpretation-changing design detail.

    From Post hoc counterfactual mediation analysis (Vansteelandt repeated regression) of SELECT RCT

  • Supplementary analyses suggested body weight and waist circumference mediation estimates may be unreliable because mediator-outcome relationships differed between treatment arms.

    The supplied story caveats mention possible bias from unintentional weight loss, comorbid illness, or frailty, but they do not reflect the profile's specific limitation: unreliability of body-weight and waist-circumference estimates due to differing mediator-MACE relationships by treatment arm.

    From Supplementary robustness/sensitivity mediation analyses within SELECT RCT

  • An alternative joint mediation analysis excluding body weight and waist circumference estimated 46.0% mediation, but remained highly imprecise with 95% CI -6.0 to 161.0.

    The story focuses on the all-mediators 31.4% estimate and does not appear to report the alternative mediator-set estimate excluding weight and waist circumference.

    From Supplementary robustness/sensitivity mediation analyses within SELECT RCT

5 things the story did carry across
  • SELECT population and intervention: adults with pre-existing cardiovascular disease, BMI ≥27 kg/m2, without diabetes, randomized to semaglutide 2.4 mg weekly versus placebo, with MACE as the outcome.
  • The analysis examined changes from randomization to 24 months in multiple candidate mediators, including body weight, waist circumference, hsCRP, HbA1c, lipids, blood pressure, eGFR, and urinary albumin-to-creatinine ratio, individually and jointly.
  • The main joint-mediator point estimate for all potential mediators combined was 31.4%, but with very wide uncertainty: 95% CI -30.1 to 143.6.
  • Single-mediator estimates were imprecise, with wide confidence intervals, including estimates for waist circumference, hsCRP, HbA1c, and body weight.
  • The abstract-level profile states that the analysis could not definitively ascribe semaglutide's MACE benefit to the evaluated known risk factors and that additional biomarkers/mediators require further investigation.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataQuantify how much of semaglutide’s MACE reduction in SELECT is mediated by changes in candidate cardiometabolic risk factors using counterfactual mediation methods (individual mediators and combinations).Post hoc counterfactual mediation analysis (Vansteelandt repeated regression) of SELECT RCTExpand

In plain English

Post hoc counterfactual mediation analysis of SELECT (semaglutide 2.4 mg weekly vs placebo) evaluated whether 24-month changes in candidate cardiometabolic risk factors mediate the trial's 20% MACE reduction, using Vansteelandt repeated regression in single- and joint-mediator models; mediation estimates were imprecise and did not conclusively explain the treatment effect.

Key findings

  • SELECT reported a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo; this analysis tested mediation of that effect.20% reduction in MACE (overall SELECT result)
  • Single-mediator models produced the largest point estimates of percent mediation for waist circumference, hsCRP, HbA1c, and body weight, but all estimates were imprecise.Waist circumference 64.0% (95% CI 27.5, 179.6); hsCRP 42.1% (95% CI 17.9, 110.5); HbA1c 29.0% (95% CI -20.7, 120.5); body weight 19.5% (95% CI -33.0, 110.7).
“In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index ≥27 kg/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo.”
What this piece can’t prove
  • Mediation estimates were imprecise (wide 95% confidence intervals, several including negative values and very large positive values).
  • Supplementary analyses indicated potential unreliability for body-weight and waist-circumference mediation estimates due to differing mediator–outcome relationships by treatment arm.
  • This is a post hoc secondary analysis of the SELECT trial; abstract does not report full diagnostics, sensitivity analyses, or assumptions checks required for causal mediation interpretation.
2secondary dataAssess robustness/credibility of mediation estimates (e.g., instability for body weight/waist circumference due to differing mediator–outcome relationships between treatment arms; alternative mediator sets excluding weight/waist).Supplementary robustness/sensitivity mediation analyses within SELECT RCTExpand

In plain English

Supplementary/robustness mediation analyses from SELECT examined stability of mediator effect estimates, flagged unreliability for body weight and waist circumference (potentially driven by differing mediator–outcome relationships between treatment arms), and re-estimated joint mediation after excluding weight/waist. Re-estimation excluding weight/waist yielded 46.0% mediation (95% CI -6.0, 161.0), while joint mediation for all mediators was 31.4% (95% CI -30.1, 143.6). Individual mediator point estimates had large CIs (e.g., waist 64.0% [27.5, 179.6], hsCRP 42.1% [17.9, 110.5], HbA1c 29.0% [-20.7, 120.5], body weight 19.5% [-33.0, 110.7]), limiting confidence in attribution of semaglutide's MACE benefit to these measured mediators.

Key findings

  • Supplementary analyses suggested unreliability of estimates for body weight and waist circumference, potentially due to differing relationships of body weight and waist change to MACE between treatment arms.
  • When variables other than body weight and waist circumference were considered, percentage mediation was 46.0% (95% CI -6.0, 161.0).46.0% (95% CI -6.0, 161.0)
“Supplementary analyses suggested unreliability of estimates for body weight and waist circumference, potentially due to differing relationship of body weight and waist change to MACE between treatment arms.”
What this piece can’t prove
  • Many mediation estimates have very wide confidence intervals that include null or implausible values, indicating imprecision.
  • Potential violation of mediation assumptions (e.g., effect modification of mediator–outcome relationship by treatment arm) was suggested and could bias mediation decomposition.
  • Re-estimated mediator sets (excluding weight/waist) remain imprecise, so robustness/sensitivity analyses do not conclusively identify mediators.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

And 9 more candidates considered.